This paper takes an inventory of the latest clinical trials in the field of Alzheimer’s disease and liver cancer in the world as of May 6, 2019. The data source is clinicaltrials.gov. We have counted those who are in the process of recruitment, recruitment completion and recruitment notices issued, excluding trials that have been completed, terminated, unknown, withdrawn and suspended.
Alzheimer’s disease Clinical Trial
As of May 6, 2019, there were 204 new drug clinical trials in the field of Alzheimer’s disease, with phase Ⅱ studies dominating-58 trials in phase Ⅰ and 110 trials in phase Ⅱ. There are 36 trials in phase Ⅲ. Clinical trials of new drugs for Alzheimer’s disease have focused on the United States and Europe. According to the location of the research institutions in the clinical trials, the top five countries were 140 in the United States, 32 in Canada, 31 in Spain, 30 in Australia and 28 in the United Kingdom. The companies that are leading clinical trials of new drugs for Alzheimer’s disease are Roche 7, Bojian 6, Lilai 6 and Genentech 5. From April 1 to 30, 2019, there were seven newly released clinical trials of new drugs for Alzheimer’s disease. Among them, there are 2 items in phase Ⅰ, 3 items in phase Ⅱ and 2 items in phase Ⅲ.
| Drug | Research phase | Institute |
| Drug:[18F]P16-129 | phase Ⅰ | Five Eleven Pharma,Inc. |
| Biological:Amniotic and Umbilical Cord Tissue Procedure | phase Ⅰ | R3 Stem Cell |
| Drug:flortaucipir F18 | phase Ⅲ | Avid Radiopharmaceuticals |
| Drug:flortaucipir F18 | phase Ⅲ | Avid Radiopharmaceuticals |
| Drug:All Subjects | phase Ⅱ | University of Wisconsin, Madison |
| Drug:[18F]PI-2620 | phase Ⅱ | Jae Seung Kim |
| Drug: PQ912|Other:Placebo | phase Ⅱ | Probiodrug AG |
Liver Cancer Clinical Trial
As of May 6, 2019, there were 346 new drug clinical trials in the field of liver cancer, with early clinical studies dominant-150 trials in phase Ⅰ and 139 trials in phase Ⅱ. There are 56 trials in phase Ⅲ. Clinical trials of new drugs for liver cancer are mainly focused on the United States and Asia. According to the statistics of the location of the research institutions of the clinical trials, the top five countries or regions are: 156 in the United States, 96 in mainland China, 45 in Taiwan, 42 in France and 35 in South Korea. The companies that are leading the clinical trials of new drugs for liver cancer are: Lilly 6, Hengrui 5, Mercado 5, Novartis 4 and Incyte Corporation3. From April 1 to 30, 2019, there were seven new drug clinical trials for liver cancer. Among them, there are 3 items in phase 1 and 4 items in phase 2.
| Drug | Research phase | Institute |
| Biological: TBI 302 | phase Ⅰ | Therapure Biopharma Inc |
| Biological: TCR redirected T cells | phase Ⅰ | Beijing 302 Hospital |
| Drug: ABX196 | phase Ⅰ | Abivax S.A. |
| Drug: Durvalumab|Drug:Sorafenib|Drug: Lenvatinib|Drug: Regorafenib|Drug: Cabozantinib | phase Ⅱ | Humanity & Health Medical Group Limited |
| Drug:Branch Chain Amino Acid|Other:maltodextrin | phase Ⅱ | Louisiana State University Health Sciences Center in New Orleans |
| Drug:Lenvatinib|Drug:Toropalimab | phase Ⅱ | Sun Yat-sen University |
| Drug:cemiplimab|Drug:Platinum Doublet | phase Ⅱ | Regeneron Pharmaceuticals |
References
1. Herring, W. J., Ceesay, P., Snyder, E., Bliwise, D., Budd, K., Hutzelmann, J., … & Michelson, D. (2019). Clinical Polysomnography Trial of Suvorexant for Treating Insomnia in Alzheimer’s Disease (P3. 6-022).
2. Sahu, B., Pihlajamaa, P., Zhang, K., Cervera, A., Hautaniemi, S., & Taipale, J. (2019). Direct conversion of human fibroblasts to liver cancer cells. bioRxiv, 525600.
Related Products
Lenvatinib maltodextrin Regorafenib